Race Oncology Ltd (RAC) - Net Assets

Latest as of December 2025: AU$23.57 Million AUD ≈ $16.68 Million USD

Based on the latest financial reports, Race Oncology Ltd (RAC) has net assets worth AU$23.57 Million AUD (≈ $16.68 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$24.77 Million ≈ $17.52 Million USD) and total liabilities (AU$1.20 Million ≈ $847.04K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RAC cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$23.57 Million
% of Total Assets 95.17%
Annual Growth Rate -12.69%
5-Year Change 16.68%
10-Year Change 292.64%
Growth Volatility 30807.86

Race Oncology Ltd - Net Assets Trend (2011–2025)

This chart illustrates how Race Oncology Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Race Oncology Ltd for the complete picture of this company's asset base.

Annual Net Assets for Race Oncology Ltd (2011–2025)

The table below shows the annual net assets of Race Oncology Ltd from 2011 to 2025. For live valuation and market cap data, see market value of Race Oncology Ltd.

Year Net Assets Change
2025-06-30 AU$16.01 Million
≈ $11.33 Million		 -12.56%
2024-06-30 AU$18.31 Million
≈ $12.96 Million		 -28.15%
2023-06-30 AU$25.49 Million
≈ $18.03 Million		 -29.42%
2022-06-30 AU$36.11 Million
≈ $25.55 Million		 +163.13%
2021-06-30 AU$13.72 Million
≈ $9.71 Million		 +141.17%
2020-06-30 AU$5.69 Million
≈ $4.03 Million		 +12.68%
2019-06-30 AU$5.05 Million
≈ $3.57 Million		 -36.32%
2018-06-30 AU$7.93 Million
≈ $5.61 Million		 +40.68%
2017-06-30 AU$5.64 Million
≈ $3.99 Million		 +38.24%
2016-06-30 AU$4.08 Million
≈ $2.89 Million		 +71605.57%
2015-06-30 AU$5.69K
≈ $4.02K		 +108.10%
2014-06-30 AU$-70.24K
≈ $-49.70K		 -100.07%
2013-12-31 AU$98.97 Million
≈ $70.02 Million		 +105884.28%
2013-06-30 AU$93.38K
≈ $66.07K		 -99.90%
2012-12-31 AU$95.85 Million
≈ $67.82 Million		 +1.48%
2012-06-30 AU$94.45 Million
≈ $66.83 Million		 -11.77%
2011-06-30 AU$107.05 Million
≈ $75.74 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Race Oncology Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 955.3% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$68.49 Million 427.76%
Other Comprehensive Income AU$9.73 Million 60.75%
Total Equity AU$16.01 Million 100.00%

Race Oncology Ltd Competitors by Market Cap

The table below lists competitors of Race Oncology Ltd ranked by their market capitalization.

Company Market Cap
Taiwan Optical Platform Co Ltd
TW:6464
 $309.57 Million
Steelcast Limited
NSE:STEELCAS
 $309.84 Million
Hansae Co
KO:105630
 $309.86 Million
M3-Brigade Acquisition V Corp. Class A Ordinary shares
NASDAQ:MBAV
 $309.89 Million
Greenpanel Industries Limited
NSE:GREENPANEL
 $309.37 Million
Transcontinental Realty Investors
NYSE:TCI
 $309.11 Million
Kizilbuk Gayrimenkul Yatirim Ortakligi AS
IS:KZBGY
 $309.08 Million
Strattec Security Corporation
NASDAQ:STRT
 $309.05 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Race Oncology Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 18,312,148 to 16,011,442, a change of -2,300,706 (-12.6%).
  • Net loss of 4,787,258 reduced equity.
  • Share repurchases of 1,060,930 reduced equity.
  • New share issuances of 1,060,928 increased equity.
  • Other comprehensive income increased equity by 944,448.
  • Other factors increased equity by 1,542,106.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-4.79 Million -29.9%
Share Repurchases AU$1.06 Million -6.63%
Share Issuances AU$1.06 Million +6.63%
Other Comprehensive Income AU$944.45K +5.9%
Other Changes AU$1.54 Million +9.63%
Total Change AU$- -12.56%

Book Value vs Market Value Analysis

This analysis compares Race Oncology Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 25.84x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 1354.17x to 25.84x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-06-30 AU$0.00 AU$2.40 x
2014-06-30 AU$-0.01 AU$2.40 x
2015-06-30 AU$0.01 AU$2.40 x
2016-06-30 AU$0.08 AU$2.40 x
2017-06-30 AU$0.11 AU$2.40 x
2018-06-30 AU$0.12 AU$2.40 x
2019-06-30 AU$0.06 AU$2.40 x
2020-06-30 AU$0.05 AU$2.40 x
2021-06-30 AU$0.10 AU$2.40 x
2022-06-30 AU$0.24 AU$2.40 x
2023-06-30 AU$0.16 AU$2.40 x
2024-06-30 AU$0.11 AU$2.40 x
2025-06-30 AU$0.09 AU$2.40 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Race Oncology Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -29.90%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -79.22%
  • • Asset Turnover: 0.35x
  • • Equity Multiplier: 1.09x
  • Recent ROE (-29.90%) is above the historical average (-121.31%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 9.46% 8.11% 0.33x 3.55x AU$-580.60K
2012 -10.85% -7.27% 0.33x 4.51x AU$-19.69 Million
2012 1.14% 1.28% 0.24x 3.76x AU$-8.50 Million
2013 -10.87% 0.00% 0.00x 1.13x AU$-19.48K
2013 6.22% 8.65% 0.25x 2.93x AU$-3.74 Million
2014 0.00% 0.00% 0.00x 0.00x AU$-85.35K
2015 -1534.53% -17810.00% 0.00x 21.89x AU$-87.84K
2016 -7.80% -1872.79% 0.00x 1.10x AU$-725.79K
2017 -74.01% -16548.99% 0.00x 1.06x AU$-4.74 Million
2018 -79.51% -3703.70% 0.02x 1.04x AU$-7.10 Million
2019 -72.46% -1601.31% 0.04x 1.04x AU$-4.16 Million
2020 -67.59% -2413.24% 0.03x 1.04x AU$-4.42 Million
2021 -46.20% -1636.61% 0.03x 1.04x AU$-7.71 Million
2022 -31.02% -1582.63% 0.02x 1.04x AU$-14.81 Million
2023 -38.93% -316.62% 0.12x 1.05x AU$-12.47 Million
2024 -75.46% -345.22% 0.20x 1.10x AU$-15.65 Million
2025 -29.90% -79.22% 0.35x 1.09x AU$-6.39 Million

Industry Comparison

This section compares Race Oncology Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $9,810,720
  • Average return on equity (ROE) among peers: -71.07%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Race Oncology Ltd (RAC) AU$23.57 Million 9.46% 0.05x $309.47 Million
Adalta Ltd (1AD) $3.70 Million -162.25% 0.87x $6.50 Million
Algorae Pharmaceuticals Ltd (1AI) $-1.33 Million 0.00% 0.00x $20.04 Million
ACRUX Ltd (ACR) $12.85 Million -73.71% 0.44x $3.20 Million
Actinogen Medical Ltd (ACW) $21.74 Million -43.69% 0.07x $105.70 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $15.45 Million
Arovella Therapeutics Ltd (ALA) $11.03 Million -40.87% 0.23x $58.08 Million
Anatara Lifesciences Ltd (ANR) $924.54K -218.83% 0.54x $1.57 Million
Alterity Therapeutics Ltd (ATH) $20.73 Million -6.40% 0.01x $76.95 Million
Amplia Therapeutics Ltd (ATX) $11.23 Million -30.16% 0.02x $50.82 Million
Avecho Biotechnology Ltd (AVE) $3.27 Million -95.48% 0.53x $28.59 Million

About Race Oncology Ltd

AU:RAC Australia Biotechnology
Market Cap
$309.47 Million
AU$437.38 Million AUD
Market Cap Rank
#14840 Global
#395 in Australia
Share Price
AU$2.40
Change (1 day)
-8.05%
52-Week Range
AU$1.13 - AU$4.70
All Time High
AU$4.70
Categories
Companies in Australia Biotechnology
About

Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across vari… Read more